ResultsIQ › Latest results › Anthem Biosciences Limited
Anthem Biosciences Limited Q2 FY27 results press release summary
NSE: ANTHEM · BSE: 544449
Results press release of 3 Nov 2026, summarised by AI from the filing.
Management expects to sustain this performance all year, without giving a figure.
Key takeaways
- Guidance Management expects to sustain this performance all year, without giving a figure.
- Margin support Q2 EBITDA of ₹3,304 Mn includes other income of ₹589 Mn (Q2 FY26: ₹478 Mn).
Anthem Biosciences Limited Q2 FY27 results
As filed: Revenue ₹594 cr (+8% year on year), EBITDA ₹271 cr (+24% year on year), PAT ₹211 cr (+22% year on year), EBITDA margin 45.7% (+588 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹418 cr (−23% year on year), EBITDA ₹151 cr (−21% year on year), PAT ₹120 cr (−12% year on year), EBITDA margin 36.0% (+63 bps). Score 18 of 100, Below trend. EBITDA margin rose 63 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 32% from last quarter. Share price after the results: +10.5% in 30 days (Nifty 500: +0.7%).
- Q4 FY26: Revenue ₹583 cr, EBITDA ₹267 cr, PAT ₹212 cr, EBITDA margin 45.8%. Not scored. No result for the same quarter last year. Share price after the results: +1.4% in 30 days (Nifty 500: +3.0%).
- Q3 FY26: Revenue ₹417 cr, EBITDA ₹163 cr, PAT ₹112 cr, EBITDA margin 39.1%. Not scored. No result for the same quarter last year. Share price after the results: +4.4% in 29 days (Nifty 500: −4.0%).
- Q2 FY26: Revenue ₹552 cr, EBITDA ₹225 cr, PAT ₹198 cr, EBITDA margin 40.8%. Not scored. No result for the same quarter last year. Share price after the results: −6.8% in 30 days (Nifty 500: 0.0%).
- Q1 FY26: Revenue ₹538 cr, EBITDA ₹196 cr, PAT ₹148 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year. Share price after the results: +10.4% in 30 days (Nifty 500: +2.2%).
Past price moves after results do not indicate future moves. Not a recommendation.
Anthem Biosciences Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (4 Nov 2026), Results deck (3 Nov 2026), Results press release (3 Nov 2026)
- Q1 FY27: Earnings call (22 Jul 2026), Results deck (21 Jul 2026), Results deck (21 Jul 2026), Results press release (21 Jul 2026), Results press release (21 Jul 2026)
- Q4 FY26: Earnings call (20 May 2026), Results deck (19 May 2026)
- Q3 FY26: Earnings call (5 Feb 2026), Results deck (5 Feb 2026), Results press release (5 Feb 2026), Results press release (5 Feb 2026), Results press release (5 Feb 2026)
- Q2 FY26: Earnings call (10 Nov 2025), Results deck (8 Nov 2025), Results press release (8 Nov 2025)
- Q1 FY26: Earnings call (14 Aug 2025), Results deck (13 Aug 2025), Results press release (13 Aug 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.